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Abstract
Overall survival (OS) is the gold- standard end point for studies evaluating autolo-
gous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment 
may be elusive due to the lengthy disease course. We analyzed the validity of two 
earlier end points, proposed in the setting of first- line chemo- /immunotherapy, as 
surrogates for OS—progression- free survival (PFS) status at 24 months (PFS24) 
and complete response at 30 months (CR30) post- ASCT. We also have investigated 
the clinical features of patients with early progression after ASCT. Data were avail-
able for 626 chemosensitive FL patients who received ASCT between 1989 and 
2007. Median follow- up was 12.2 years from ASCT. In the PFS24 analysis, 153 
(24%) patients progressed within 24 months and 447 were alive and progression- 
free at 24 months post- ASCT (26 who died without disease progressions within 
24 months were excluded). Early progression was associated with shorter OS (hazard 
ratio [HR], 6.8; P = 0.00001). In the subgroup of patients who received an ASCT 
in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% 
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Introduction
Follicular lymphoma (FL) is the most common of indolent 
lymphoma. The combination of conventional chemo-
therapy, radiotherapy, anti- CD20 immunotherapy, and 
stem cell transplantation has contributed to modifying 
the natural history of FL [1–3]. FL is characterized by a 
long median overall survival (OS), however, FL remains 
largely incurable, characterized by repeated remission and 
recurrence over many years [4]. Thus, demonstration of 
an OS benefit requires a long observation period and 
large numbers of patients [5, 6]. For this reason, the OS 
assessment to evaluate the efficacy of the different thera-
peutic alternatives in FL can be elusive. Progression- free 
survival (PFS) is presently the principal end point for 
regulatory approval of new agents. In the pre- rituximab 
era, a relationship between higher complete response (CR) 
rates and improved PFS or OS, was not consistently seen 
[7, 8]. However, in the era of novel targeted therapeutics 
that offers clinical benefit for long period of times, PFS 
may as well have fleeting relevance [9, 10]. This extended 
PFS prolongs the duration of clinical trials and limits the 
ability to approve new effective therapeutic options against 
FL. Therefore, the identification of alternative or surrogate 
end points that are measured earlier but can reliably pre-
dict PFS treatment effect has been a critical need for 
decades.
In an attempt to be able to select patients with poor 
outcome soon in the course of the disease; an observa-
tional study of 588 FL patients from the National 
LymphoCare Study (NLCS) treated with the first- line 
immunochemotherapy showed that early progression pre-
dicted poor outcome [11]. After a median follow- up of 
7 years, those with disease progression within 2 years of 
first- line treatment had very poor outcomes, with 5- year 
OS of 50% compared with 5- year OS of 90% for patients 
in the reference group who did not experience an early 
relapse. Cox regression analysis demonstrated that early 
relapse was associated with markedly reduced OS with a 
hazard ratio of 7.17 when compared with the reference 
group. Additionally, the Follicular Lymphoma Analysis of 
Surrogacy Hypothesis (FLASH) investigators have recently 
performed a meta- analysis of 13 randomized trials of 
first- line treatment in FL which included more than 3000 
patients treated with a variety of regimens. They found 
that CR rate at 30 months could predict PFS and pro-
posed this as a possible end point for clinical trials in 
FL [12].
Autologous stem cell transplantation (ASCT) is com-
monly used in relapsed follicular lymphoma (FL), having 
shown an overall survival (OS) benefit in randomized 
studies [13]. However, ASCT is currently rarely used in 
first remission because randomized studies have shown 
no OS benefit in this setting, despite some studies dem-
onstrating improved progression- free survival (PFS) [14–
18]. OS is still the gold- standard end point for studies 
evaluating ASCT in FL. In the present study, we want 
to analyze the value of alternative end points associated 
with prognosis; that have been proposed as surrogates 
for OS/PFS in the context of first- line chemo- /immuno-
therapy, in a large and lengthy follow- up series of FL 
patients from the Spanish GELTAMO database who under-
went an ASCT between 1989 and 2007 after chemo or 
chemoimmunotherapy, either as first or subsequent 
responses. We also have investigated the clinical features 
of patients with early progression after ASCT, to better 
understand its role in FL.
Patients and Methods
Study design and participant
The GELTAMO registry database includes 655 patients 
with nontransformed FL who received ASCT between 1 
January 1989, and 31 December 2007 at 44 centers in 
Spain. All data were updated with a cut- off date of 31 
July 2014. Regarding histology, patients were classified 
per the Working Formulation into follicular small cleaved 
cell, follicular mixed small cleaved and large cell, or fol-
licular large cell, and according to the Revised European- 
American Classification of Lymphoid Neoplasms as NHL 
follicular grade 1, 2, or 3 [19].
Response and disease status
Patients’ disease status was classified according to whether 
they had achieved their first (CR1), second (CR2), or 
third (CR3) CR, or their first (PR1) or subsequent (PR ≥ 2) 
CI, 3.9–30.2; P < 0.00001). In the CR30 analysis, 183 of 596 (31%) response- 
evaluable patients progressed/died with 30 months post- ASCT. The absence of 
CR30 was associated with shorter OS (HR, 7.8; P < 0.00001), including in patients 
with prior rituximab (HR, 8.2). PFS24 and CR30 post- ASCT are associated with 
poor outcomes and should be primary end points. Further research is needed to 
identify this population to be offered alternative treatments.
doi: 10.1002/cam4.1217
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partial response (PR) to (immuno)- chemotherapy at the 
time of HDT/ASCT. According to GELTAMO guidelines, 
CR was defined as the disappearance of all clinical evi-
dence of disease, with normalization of X- rays, CT scans, 
and laboratory values that had been abnormal before 
therapy; PR was defined as a ≥50% reduction in measur-
able disease for ≥1 month; resistant/refractory disease was 
defined as lymphoma that progressed during initial com-
bination chemotherapy or a response of less than PR to 
salvage therapy [20, 21]. From 1999 onwards, response 
criteria used were those recommended internationally at 
the time of HDT/ASCT [22, 23].
Statistically analysis
Patient- , disease- , and transplantation- related factors were 
compared between groups using the Χ2 test for categori-
cal variables and the Mann- Whitney test for continuous 
variables. OS were analyzed using the Kaplan- Meier 
method and differences were assessed by the log- rank 
test. All P- values were two- sided and P < 0.05 was con-
sidered statistically significant. For analysis of PFS24 as 
a surrogate end point for OS, patients were divided into 
two groups: those with disease progression within 2 years 
from ASCT, and those alive without progression at 2 years 
from ASCT; 26 patients who died without disease pro-
gression within 2 years were excluded. In the two groups, 
OS was measured from time of disease progression and 
from the 2- year post- ASCT landmark, respectively [9] 
For analysis of CR30, the two groups comprised: those 
not in CR at 30 months post- ASCT (due to never achiev-
ing or relapsing from CR), and those in CR at post- ASCT 
evaluation (~3 months) who had not relapsed at 
30 months. In these groups, OS was measured from the 
time of relapse/progression from CR/PR or death, and 
from the 30- month post- ASCT landmark, respectively. A 
Cox model was used to calculate the associations between 
PFS24 status and OS, and CR30 status and OS. To iden-
tify factors associated with early POD, logistic regression 
analysis was performed with backward selection (removing 
factors when P > 0.05).
Results
Of the 655 patients; there were 203 who underwent ASCT 
in first complete response (CR), 140 in first partial response 
(PR), 174 in second CR, 28 in third CR, 81 in second 
or later PR, and 29 with resistant/refractory disease. These 
latter patients were excluded, leaving 626 chemosensitive 
patients for inclusion in these analyses. Demographic and 
disease characteristics at diagnosis and treatment- and 
transplantation- related parameters for all 626 patients are 
summarized in Table 1.
At data of cut- off (31 July 2014) median follow- up for 
survival from HDT/ASCT was 12.2 years (IQR: 8.1–15.6) 
and from FL diagnosis was 14.2 years (IQR: 10.9–18). 
For patients who were rituximab- naïve prior to HDT/
ASCT respective values from the time of ASCT were 
14.2 years and 16.4 years, and in patients with prior 
rituximab respective values were 9.0 and 12.0 years.
Median age at diagnosis was 47 years (range: 18–70), 
307 (49%) were male, 97 of 310 (31%) patients with 
available data had high- risk FL International Prognostic 
Index (FLIPI) score, and 121 of 301 (40%) patients had 
high- risk FLIPI 2 score. As first- line therapy 76% of the 
patients (443/583) received an anthracycline- based regi-
men. Prior to HDT/ASCT, 70% of patients received 
chemotherapy and 30% received chemotherapy plus rituxi-
mab. Of 179 patients with previous rituximab exposure 
(Table 1), 120 received rituximab as first- line therapy 
(induction or maintenance) and 101 as part of salvage 
therapy (induction or maintenance); 42 patients received 
rituximab in both scenarios. A total of 89 patients under-
went ASCT in first response (CR1, n  =  67; PR1, n  =  22), 
and 90 patients underwent ASCT in relapse (CR  ≥ 2, 
n =  67; PR  ≥ 2, n =  23) who had been treated with 
rituximab before transplantation. Median time from diag-
nosis to HDT/ASCT was 1.9 years (IQR: 0.9–3.5); 28% 
of patients received HDT/ASCT within 1 year after diag-
nosis. For transplantation, peripheral blood was used as 
the progenitor cell source in 86% of patients (median 
number of CD34+ cells infused was 3 × 106/kg [range: 
0.2–37.6]). Only 16% of patients received total body 
irradiation- containing conditioning regimens.
A total of 203 (31%) patients underwent ASCT after 
achieving CR1 (85 of 199 patients in whom data were 
available [43%] required more than one line of chemo-
therapy to achieve CR), 174 (27%) were transplanted in 
CR2, 28 (4%) in CR3, 140 (21%) in PR1 (66 of 134 
patients in whom data were available [49%] required more 
than one line of chemotherapy to achieve PR) and 81 
(12%) in PR ≥ 2. Post- HDT/ASCT disease status was 
assessable in 640 patients; 585 (91.4%) maintained or 
upgraded to CR, 32 (5%) maintained or upgraded to PR, 
and 23 (3.6%) progressed or died. The median duration 
of first response for patients not transplanted as part of 
first- line therapy was 1.4 years (IQR: 0.75–3.1).
In the analysis of PFS24, 153 of 626 (24%) patients 
progressed within 24 months post- ASCT, including 62 of 
405 (15%) patients who underwent ASCT in CR, and 24 
of 179 (13%) patients treated with rituximab- containing 
chemotherapy before ASCT. 447 (71%) patients overall, 
including 325 (80%) who underwent ASCT in CR, and 
146 (82%) patients with prior rituximab, were alive 
and progression- free at 2 years post- ASCT, while 26, 18, 
and 9 patients, respectively, were excluded, having died 
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without disease progression within 2 years. Among patients 
transplanted at first response (n = 343: 203 in CR +140 
in PR) o in the setting of relapse (n = 283: 174 in 
CR2 + 28 in CR3 + 81 in PR ≥ 2); a total of 81 of 343 
(23.5%) and of 72 of 283 (25.5%) progressed within 
24 months post- ASCT (P > 0.5). 248 and 199 were alive 
and progression- free at 2 years post- ASCT, while 14 and 
12 patients were excluded, having died without disease 
progression within 2 years; respectively. In the subgroup 
of patients transplanted and relapsed after a rituximab 
regimen only 11 of 87 (n = 13%) progressed within the 
first 2 years post- ASCT.
For the 153 patients who progressed within 24 months 
post- ASCT, the median age at diagnosis was 48 years 
(range, 28–70 years), and 60% of patients were male. 
Patients who progressed within 24 months post- ASCT 
were more likely to be male (93/153 vs. 207/447; P=.002), 
to have at diagnosis an Eastern Cooperative Oncology 
Group (ECOG) Performance Status (PS) >1 (28/141 vs. 
47/298; P = 0.007), bone marrow infiltration (96/144 vs. 
201/413; P = 0.0005), high lactate dehydrogenase (LDH) 
level (45/136 vs. 91/38; P = 0.04) and more than four 
nodal areas affected (40/80 vs. 91/246 P = 0.04). There 
were also fewer patients who received rituximab before 
ASCT in the subgroup of patients who progressed within 
24 months post- ASCT (24/143 vs. 146/423; P < 0.00001). 
For patients undergoing ASCT in 2nd/3rd CR or PR ≥ 2; 
there were more patients with a duration of first remis-
sion less than 12 months in the subgroup of patients 
who progressed within 24 months post- ASCT (27/47 vs. 
42/136; P = 0.001). In the multivariate analysis, factors 
associated with early POD were poor performance status 
(≥2) (P = 0.0005) and the absence of rituximab before 
ASCT (P = 0.002).
Early progression was associated with shorter OS. In 
all the patients (n = 626), OS from a risk- defining event 
at 5 years in the patients who progressed within the 
24 months post- ASCT was 39%, and at 10 years was 
Table 1. Main clinical features at diagnosis and treatment variables of 
the series.
Characteristics Patient series (n = 626)
Age at diagnosis, years

























<6 cm 192/449 (43%)
















Time from diagnosis to HDT/ASCT, years
≤1 171/609 (28%)
>1 438/609 (72%)





PR ≥ 2 81 (13%)
Received rituximab prior to HDT/ASCT
Yes 179/592 (30%)
No 413/592 (70%)
TBI- based conditioning regimen
Yes 102/625 (16%)
Characteristics Patient series (n = 626)
No 523/625 (84%)
Use of PBPC for ASCT
Yes 492/573 (86%)
No 81/573 (14%)
Data are n/N (%) unless otherwise stated. In some categories the % 
values may not sum to 100% due to rounding. BM, bone marrow; FLIPI, 
Follicular Lymphoma International Prognostic Index; CR, complete re-
sponse; PR, partial response; ASCT, autologous stem cell transplanta-
tion; HDT, high- dose therapy; TBI, total body irradiation; PBPC, 
peripheral blood progenitor cells.
1Performance status according to the ECOG scale: 0–1=low level of 
functional impairment, 2–4 = high level of functional impairment. 
2According to normal values of each laboratory.
(Continued)
Table 1 (Continued)
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27% compared with 89% and 80%, respectively, for the 
reference group. The hazard ratio (HR) for death was 
6.8 (95% confidence interval [CI], 5.2–9.0; P = 0.00001) 
(Fig. 1A); among patients transplanted in CR (n = 405), 
the HR was 8.9 (95% CI, 5.8–13.7; P < 0.00001) (Fig. 1B), 
and for patients transplanted in PR (n = 221) the HR 
was 3.9 (95% CI, 2.6–5.8; P < 0.00001). In patients trans-
planted in the setting of relapse (n = 283); OS from a 
risk- defining event at 5 years in the patients who pro-
gressed within the 24 months post- ASCT was 31%, and 
at 10 years was 22% compared with 85% and 75%, 
respectively, for the reference group; with an HR of 6.5 
(95% confidence interval [CI], 3.7–8.71; P = 0.00001). 
Finally, in patients with prior rituximab (n = 179) the 
HR was 6.9 (95% CI, 3.5–13.7; P = 0.00001) (Fig. 1C); 
this association of PFS24 with OS was seen independent 
of patients being transplanted in first response (HR, 5.0 
[95% CI, 1.8–13.5; P < 0.00001), or in the setting of 
salvage therapy (n = 87) (HR, 11.3 [95% CI, 3.9–30.2; 
P < 0.00001).
To further characterize the effect of progression within 
the first 2 years after ASCT, OS from time of progression 
was evaluated for patients whose disease progressed early 
versus patients whose disease progressed more than 2 years 
after ASCT. Patients with early progression had inferior 
OS compared with those progressions occurred after 2 years 
(HR, 1.9; 95% CI, 1.45 to 2.5; P = 0.000006).
We have further information on 220 patients who 
relapsed post- ASCT. A total of 24 patients were consoli-
dated with an allogenic stem cell transplantation. Of them, 
12 patients (50%) are still alive and free of FL at last 
follow- up. The causes of death of the remaining 12 patients 
were progression of FL in four cases, infection in two 
cases, graft versus host disease in four cases, and non- 
specified non- relapsed mortality in two cases.
For the analysis of CR30, 616 patients had response 
assessments post- ASCT: 567 (92%) were in CR, 29 (5%) 
were in PR and 20 (3%) progressed or died. In 563 
patients with available data, 175 (31%) received rituximab 
prior to ASCT, of whom 134 were transplanted in CR 
and 89 while in first response. Of 596 patients with 
CR/PR post- ASCT, 183 (31%) progressed or died within 
30 months post- ASCT. The absence of CR in 30 months 
was associated with shorter OS: the HR for death was 
7.8 (95% CI, 6.0–10.3; P < 0.00001) (Fig. 2). This asso-
ciation was retained in patients who received rituximab 
before ASCT (HR, 8.2 [95% CI, 4.5–15.1; P < 0.00001).
Discussion
In aggressive lymphomas, such as diffuse large B- cell lym-
phoma, early relapse post- ASCT is widely accepted as 
associated with poor prognosis [24]. However, in FL there 
is only one study that demonstrates that an early relapse 
post- ASCT has a negative impact on OS [25]. This report 
represents the first analysis of chemosensitive FL patients 
receiving ASCT that suggests that PFS24 could be a valid 
surrogate and primary end points for OS in this setting. 
The findings from our large patient series offer validation 
of previously published data outside ASCT. Casulo et al. 
[11] have identified a subgroup of FL patients treated 
with chemoimmunotherapy who progressed within the 
first 2 years after diagnosis and who are at high risk for 
death after treatment. Another study [26] has recently 
confirmed this data in a 7.7 years median- follow cohort 
of 94 patients with FL who also received first- line chemo-
immunotherapy .
Additionally, it has been demonstrated in a large series 
of 920 newly diagnosed FL that event- free survival (EFS) 
at 12 and 24 months from diagnosis in patients treated 
with first- line chemoimmunotherapy is an extremely pow-
erful prognostic indicator of outcome in FL [27]. Our 
results show that persistence of complete response at 
30 months after ASCT could as well be a surrogate for 
OS in FL who are autografted. These results are consist-
ent with the data obtained by Shi Q et al. [12] in a 
pooled analysis of randomized chemotherapy, immuno-
therapy, or chemoimmunotherapy trials that demonstrated 
that CR at 30 months after initiation of induction treat-
ment may serve a surrogate end point for PFS in the 
setting of first- line FL treatment trial.
From this study, some clinical characteristics at diagnosis 
such as older age, male sex, ECOG PS > 1, bone marrow 
infiltration, high lactate dehydrogenase level (LDH) or 
more than four nodal areas affected were associated with 
progression within 24 months post- ASCT and, therefore, 
with poor outcome. Duration of first remission less than 
12 months also predicted for an early relapse. Murakami 
et al. [26] also identified high LDH levels as a predictor 
of early death in patients treated with first- line chemoim-
munotherapy. Furthermore, only ECOG PS>1 and the 
fact of being rituximab- naïve at the moment of ASCT 
had statistical significance in the multivariate analysis. 
Neither the moment (1st or subsequent responses) nor 
the status of the disease at ASCT (CR or PR) was associ-
ated with the incidence of early progression. The fact 
that an early relapse after ASCT in rituximab exposed 
patients seems to be less frequent than in rituximab- naive, 
has already been demonstrated in diffuse large B- cell 
lymphoma [24]. Nevertheless, in our series, there are still 
13% of patients who will have an early relapse post- ASCT 
after a rituximab- based therapy; even when transplanted 
in CR1. A positive impact of rituximab sensitivity on the 
results of ASCT has been recently suggested by the 
Hutchinson Cancer Research Center in 35 relapsed FL 
patients [28], however, the poor outcomes of patients 
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Figure 1. Evaluation of OS according to PFS24 status post- ASCT. Disease progression within 24 months from ASCT was associated with poorer OS, 
in (A) the overall population, (B) patients who underwent ASCT in CR, and (C) patients who received rituximab prior to ASCT. Black line: Patients alive 
and progression- free at 24 months post- ASCT; OS measured from landmark of 24 months. (A) n = 447, (B) n = 325, (C) n = 146. Gray line: Patients 
who progressed within 24 months post- ASCT; OS measured from time of progression. (A) n = 153, (B) n = 62, (C) n = 24.
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who relapse soon after ASCT in the rituximab era has 
not been described.
We agree with Casulo et al. [11] with the idea that 
ASCT may potentially abrogate the negative prognostic 
effect of early relapse after a chemoimmunotherapy regi-
men because the salvage chemotherapy followed by ASCT 
has an established role in relapsed FL [13, 29–31]. 
Nevertheless, from our data, we can conclude that although 
ASCT at first relapse could be a reasonable option in 
some high- risk FL patients; there are still FL populations 
in whom consolidation with allogenic stem cell transplan-
tation or new therapeutic options are needed. Additionally, 
there are some patients autografted in CR1 after chemo 
or chemoimmunochemotherapy, who will die soon after 
ASCT. The identification of these patients soon during 
the course of the disease would be of capital interest. 
Some genetic alterations, such as chromosomal gains and 
losses or rearrangements of P53 or MYC, have been 
implicated in poor outcomes in FL [32, 33]. Additionally, 
novel biomarkers that incorporate both clinical and genetic 
determinants of poor risk are being developed with the 
hope of identifying high- risk patients at diagnosis to offer 
biologically rational targeted therapies. Recently it has been 
published in Lancet Oncology that the integration of the 
mutational status of seven genes (EZH2, ARID1A, MEF2B, 
EP300, FOXO1, CREBBP, and CARD11) by DNA deep 
sequencing with clinical risk factors improves prognostica-
tion for patients with follicular lymphoma receiving first- 
line immunochemotherapy [34].
The clinical implications of early progression after ASCT 
are highly relevant to improve patient survival. This issue 
is of especial interest in patients who are autografted at 
relapse after a chemoimmunotherapy rescue regimen, 
because this strategy remains a standard of care nowadays. 
In this population, a progression during the first 24 months 
from ASCT carried an increased risk of death with a 
hazard ratio of 11.3 and the absence of CR at 30 months 
post- ASCT was associated with shorter OS with and HR 
of 8.1. The effect of early progression after ASCT with 
novel- chemotherapy- containing regimens will require vali-
dation in future studies.
Based on our data, we cannot recommend PFS 24 or 
CR 30 as a better end point in FL patients receiving an 
ASCT. As PFS 24 is an end point that can be evaluated 
in a shorter period of time since ASCT, and probably 
with less exigent criteria; we feel that PFS24 could be 
used as the preferred end point. Nevertheless, it is not 
clear, and efforts should persist in the rational design of 
clinical trials that risk stratify FL patients undergoing ASCT 
and evaluate novel end points in this disease.
Some limitations of our analysis should be noted, spe-
cifically the retrospective design and the fact that histologic 
results were not centrally reviewed. However, we believe 
these issues are not likely to have affected our conclusions 
because previous data have suggested a high degree of 
accuracy in community diagnosis of FL.
Based on our findings, we propose that PFS24 and 
CR30 should be used as primary end points and as sur-
rogates for OS in studies of FL patients receiving ASCT. 
Disease progression within 2 years and absence of CR at 
30 months post- ASCT define new high- risk groups who 
should be ideally identified soon in order to be offered 
Figure 2. Evaluation of OS according to CR30 status post- ASCT. Patients who were not in CR at 30 months post- ASCT had poorer OS. Black line: 
Patients in CR at 30 months post- ASCT; OS measured from landmark of 30 months (n = 413). Gray line: Patients not in CR at 30 months post- ASCT; 
OS measured from time of relapse/progression or death (n = 183).
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different therapeutic strategies, such as allogenic stem cell 
transplantation or novel drugs. Different diagnostic tools 
such as means of targeted sequencing or gene expression 
profiling would be essential to select this high- risk group 
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